Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.83 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.65 |
| ▸ | ERN2 | Q76MJ5 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638056 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1637715 | 0.89 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL12668365 | 0.83 | PIK3CB (0.85) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12666529 | 0.83 | PIK3CB (0.79) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1637728 | 0.82 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1638481 | 0.81 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638221 | 0.80 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL12668363 | 0.80 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638113 | 0.80 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638119 | 0.80 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |